Yuri Maricich - 03 Aug 2026 Form 4 Insider Report for Camp4 Therapeutics Corp (CAMP)

Reporting relationship: Chief Medical Officer
Issuer ticker: CAMP
Reported as of: 03 Aug 2026
Net transaction value: +$10,809
SEC form: 4
Accepted by SEC: 05 Aug 2026, 17:08:56 UTC
Prior SEC filing: 03 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Kelly Gold, as Attorney-in-Fact

Key filing fact

Yuri Maricich filed Form 4 for Camp4 Therapeutics Corp (CAMP) on 05 Aug 2026.

Key facts

This page summarizes Yuri Maricich's Form 4 filing for Camp4 Therapeutics Corp (CAMP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Aug 2026, 17:08.

Change

Previous filing in this sequence was filed on 03 Apr 2026.
Current net transaction value: +$10,809.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001881045 Primary reporting owner

Maricich Yuri

Relationship: Chief Medical Officer
Address: C/O CAMP4 THERAPEUTICS CORPORATION, ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL., CAMBRIDGE
Signature: /s/ Kelly Gold, as Attorney-in-Fact
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAMP transaction

Common Stock

Purchase

Transaction value: $10,809
Shares: +6,551
Change %: +108%
Price: $1.65
Shares after: 12,611
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.